1989
|
Sign up to set email alerts
Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes
Search citation statements
Order By: Relevance
Paper Sections
Select...
14
4
0
0
Citation Types
0
8
0
0
Year Published
Range
1990
19902023
2023Publication Types
Select...
17
Relationship
0
17
Authors
Journals
Cited by 17 publications
(8 citation statements)
References 18 publications
0
8
0
0
Order By: Relevance
Smart CitationsHow this paper cites the one you are viewing
“……”
Section: Fotemustine-based Regimen
mentioning
confidence: 92%
Smart CitationsHow this paper cites the one you are viewing
“……”
Section: Fotemustine-based Regimen
mentioning
confidence: 92%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Overall, FEAM conditioning was well tolerated. Mucositis reached G3/G4 severity in only 30% of cases (median duration 7 days, range [4][5][6][7][8][9][10][11][12][13][14], while G2/G3 chemotherapy-induced nausea and vomiting was documented in 47% of patients, without any G4 episodes. Similarly, 17 and 7% of patients experienced G2 and G3 diarrhea, while no G4 events were observed.…”
Section: Patient Characteristics
mentioning
confidence: 99%
“…11,12 In addition, as FTM does not significantly alter glutathione reductase activity, a more favorable pulmonary toxicity profile for this agent can be predicted compared with BCNU. 13 In fact, several clinical trials have confirmed that FTM, unlike other nitrosoureas, shows no significant pulmonary toxicity. [14][15][16] With regards to antitumor activity, a phase II study by Jacquillat et al, 17 showed that administration of a nonmyeloablative schedule of FTM (100 mg/m 2 on days 1, 8 and 15 (induction), followed after 4-5 weeks by a single 100 mg/m 2 maintenance dose, every 21 days), induced objective clinical responses in 7 of 13 heavily pre-treated patients with hematologic malignancies including HL and NHL; thrombocytopenia was the most commonly observed toxicity.…”
Section: Introduction
mentioning
confidence: 95%
Smart CitationsHow this paper cites the one you are viewing
“…Compound 134 was found 179 to be inactive against murine cancers which were resistant to BCNU. Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%
“…Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation. g Percentage of treated animals surviving on day 60 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%
Smart CitationsHow this paper cites the one you are viewing
“……”
Section: Fotemustine-based Regimen
mentioning
confidence: 92%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Overall, FEAM conditioning was well tolerated. Mucositis reached G3/G4 severity in only 30% of cases (median duration 7 days, range [4][5][6][7][8][9][10][11][12][13][14], while G2/G3 chemotherapy-induced nausea and vomiting was documented in 47% of patients, without any G4 episodes. Similarly, 17 and 7% of patients experienced G2 and G3 diarrhea, while no G4 events were observed.…”
Section: Patient Characteristics
mentioning
confidence: 99%
“…11,12 In addition, as FTM does not significantly alter glutathione reductase activity, a more favorable pulmonary toxicity profile for this agent can be predicted compared with BCNU. 13 In fact, several clinical trials have confirmed that FTM, unlike other nitrosoureas, shows no significant pulmonary toxicity. [14][15][16] With regards to antitumor activity, a phase II study by Jacquillat et al, 17 showed that administration of a nonmyeloablative schedule of FTM (100 mg/m 2 on days 1, 8 and 15 (induction), followed after 4-5 weeks by a single 100 mg/m 2 maintenance dose, every 21 days), induced objective clinical responses in 7 of 13 heavily pre-treated patients with hematologic malignancies including HL and NHL; thrombocytopenia was the most commonly observed toxicity.…”
Section: Introduction
mentioning
confidence: 95%
Smart CitationsHow this paper cites the one you are viewing
“…Compound 134 was found 179 to be inactive against murine cancers which were resistant to BCNU. Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%
“…Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation. g Percentage of treated animals surviving on day 60 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%
Smart CitationsHow this paper cites the one you are viewing
“……”
Section: Fotemustine-based Regimen
mentioning
confidence: 92%
Abstract
Smart CitationsHow this paper cites the one you are viewing
“…Overall, FEAM conditioning was well tolerated. Mucositis reached G3/G4 severity in only 30% of cases (median duration 7 days, range [4][5][6][7][8][9][10][11][12][13][14], while G2/G3 chemotherapy-induced nausea and vomiting was documented in 47% of patients, without any G4 episodes. Similarly, 17 and 7% of patients experienced G2 and G3 diarrhea, while no G4 events were observed.…”
Section: Patient Characteristics
mentioning
confidence: 99%
“…11,12 In addition, as FTM does not significantly alter glutathione reductase activity, a more favorable pulmonary toxicity profile for this agent can be predicted compared with BCNU. 13 In fact, several clinical trials have confirmed that FTM, unlike other nitrosoureas, shows no significant pulmonary toxicity. [14][15][16] With regards to antitumor activity, a phase II study by Jacquillat et al, 17 showed that administration of a nonmyeloablative schedule of FTM (100 mg/m 2 on days 1, 8 and 15 (induction), followed after 4-5 weeks by a single 100 mg/m 2 maintenance dose, every 21 days), induced objective clinical responses in 7 of 13 heavily pre-treated patients with hematologic malignancies including HL and NHL; thrombocytopenia was the most commonly observed toxicity.…”
Section: Introduction
mentioning
confidence: 95%
Smart CitationsHow this paper cites the one you are viewing
“…Compound 134 was found 179 to be inactive against murine cancers which were resistant to BCNU. Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%
“…Various aspects of the metabolism and pharmacokinetics [180][181][182] of 134 were reported. Fotemustine was shown 180 to be a weak inhibitor of glutathione reductase activity from rat e Defined in section V. f Percentage of treated animals surviving on day 45 after tumor implantation. g Percentage of treated animals surviving on day 60 after tumor implantation.…”
Section: Aliphatic Analogs
mentioning
confidence: 99%